Crystal structure of the human androgen receptor ligand binding domain bound with TIF2(iii) 740-753 peptide and R1881

METHYLTRIENOLONE; 17BETA-HYDROXY-17METHYL-19NORANDROSTA-4,9,11-TRIEN-3-ONE; R1881

Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance

14-mer fragment of Nuclear receptor coactivator 2

NCOA-2; TRANSCRIPTIONAL INTERMEDIARY FACTOR 2

PIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMG
WRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDEL
RMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGK
VKPIYFHTQ

human AR LBD (663-919) with thrombin cleavable NH2-terminal HIS tag

100mM BTP, 0.6 M Na/K Tartrate, pH 7.90, VAPOR DIFFUSION, HANGING DROP, temperature 293K

Androgen Receptor LBD bound with AR20-30 peptide and R1881

Androgen Receptor LBD bound with R1881 and no peptide

14-MER FRAGMENT OF TRANSCRIPTIONAL INTERMEDIARY FACTOR 2, RESIDUES 740-753

Gros, Grosse-Kunstleve, Jiang, Kuszewski, Nilges, Pannu, Read, Rice, Simonson, Warren and Molecular Simulations Inc., (Badger, Berard, Kumar, Szalma, Yip).

CRYSTAL STRUCTURE; HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN; TRANSCRIPTIONAL INTERMEDIARY FACTOR 2 740-753; R188, TRANSCRIPTION